Zhengye Biotechnology Holding (ZYBT) Payables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Payables for 3 consecutive years, with $15.7 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Payables fell 5.52% year-over-year to $15.7 million in Q4 2025; TTM through Dec 2025 was $15.7 million, a 5.52% decrease from a year earlier, with the FY2025 full-year figure at $15.7 million, down 5.52% from the prior year.
• Payables was $15.7 million for Q4 2025 at Zhengye Biotechnology Holding, down from $17.4 million in the prior quarter.
• Over five years, Payables peaked at $17.4 million in Q2 2025 and troughed at $6.7 million in Q4 2023.
• A 3-year average of $14.1 million and a median of $16.2 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables surged 149.72% in 2024 and decreased 5.52% in 2025, its largest moves.
• Over 3 years, Payables stood at $6.7 million in 2023, then jumped by 149.72% to $16.6 million in 2024, then slipped by 5.52% to $15.7 million in 2025.
• The last three Payables figures came in at $15.7 million (Q4 2025), $17.4 million (Q2 2025), and $16.6 million (Q4 2024), per Business Quant data.